866-997-4948(US-Canada Toll Free)

Global Ophthalmics Partnering 2010-2015: Deal trends, players and financials

Published By :

Current Partnering

Published Date : Oct 2015

Category :

Therapeutic Area

No. of Pages : 489 Pages

The Global Ophthalmics Partnering 2010-2015 report provides an understanding and access to the ophthalmics partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in ophthalmics partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Ophthalmics partnering contract documents
Top ophthalmics deals by value

The Global Ophthalmics Partnering 2010-2015 report provides an understanding and access to the ophthalmics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter ophthalmics partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors ophthalmics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest ophthalmics agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all ophthalmics partnering deals announced since 2010 including financial terms where available including over 200 links to online deal records of actual ophthalmics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of the report provide an orientation of ophthalmics dealmaking and its associated business and partnering activities. This chapter provides an overall introduction to the report and what you will learn from it, whilst chapter 2 provides an overview of the trends in ophthalmics deal making since 2010, categorizing by deal type, industry sector, stage of development and technology type.

A popular section with readers; chapter 3 covers the average financial deal terms for deals signed in the ophthalmics field with a stage of development announced. Deals are listed and sectioned by average headlines, upfront payments, milestone payments and royalty rates. The median values of these deals are then presented by stage of development at signing.

Numerous tables and figures are weaved within the report to support the findings and illustrate the trends and activities in ophthalmics partnering and dealmaking since 2010.

Chapter 4 covers the leading ophthalmics deals that have been announced over the past five years. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Full deal contract documents where available for each deal are indicated by a yes/no symbol. Within this chapter the most active ophthalmics deal makers are also listed as well as the deal making activities and the number of deals entered into by the big pharma and biotech companies.

Chapter 5 acts as a contracts reference directory chapter providing a full comprehensive and detailed list of the ophthalmics partnering deals signed and announced since January 2010. This chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and therapy focus. In order for readers to view full details of each agreement the report is formatted so that each deal title links via Weblink to an online version of the actual deal at Current Agreements deals and alliances database.

In conclusion, this report gives prospective dealmakers a thorough overview of all the deals announced in the ophthalmics field preparing them with everything they need to know about partnering in the research, development and commercialization of ophthalmics technologies and products.

A full appendix is provided at the very end of the report which lists all the ophthalmics deals announced since 2010 categorized by company A-Z, deal type, stage of development, technology and therapy. Where available contract documents are supplied, these documents include additional deal information in comparison to only the brief summary that is provided through a press release. Readers can analyze the contracts fully by reviewing the detailed terms between the parties under which monies and licensing rights are exchanged. The appendix is useful for looking at all the deals signed by one specific company.

Report scope

Global Ophthalmics Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to ophthalmics trends and structure of deals entered into by leading companies worldwide.

Global Ophthalmics Partnering 2010-2015 includes:

Trends in ophthalmics dealmaking in the biopharma industry since 2010
Analysis of ophthalmics deal structure
Access to headline, upfront, milestone and royalty data
Access to around 400 ophthalmics deal records
The leading ophthalmics deals by value since 2010

In Global Ophthalmics Partnering 2010-2015, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Ophthalmics Partnering 2010-2015 report provides comprehensive access to available deals and contract documents for over 400 ophthalmics deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Benefits
Global Ophthalmics Partnering 2010-2015 provides the reader with the following key benefits:

• In-depth understanding of ophthalmics deal trends since 2010
• Access ophthalmics deal headline, upfront, milestone and royalty data
• Research hundreds of actual contracts between ophthalmics partner companies
• Comprehensive access to over 400 links to actual ophthalmics deals entered into by the world’s biopharma companies
• Benchmark the key deal terms companies have agreed in previous deals
• Identify key terms under which companies partner ophthalmics opportunities
• Uncover companies actively partnering opthalmics opportunities

 

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in ophthalmics dealmaking2.1. Introduction

2.2. Ophthalmics partnering over the years
2.3. Big pharma ophthalmics dealmaking activity
2.4. Big biotech ophthalmics dealmaking activity
2.5. Ophthalmics partnering by deal type
2.6. Most active in ophthalmics partnering
2.7. Ophthalmics partnering by industry sector
2.8. Ophthalmics partnering by stage of development
2.9. Ophthalmics partnering by technology type
2.10. Ophthalmics partnering by specific therapy indication
2.11. Average deal terms for ophthalmics
2.11.1 Ophthalmics headline values
2.11.2 Ophthalmics upfront payments
2.11.3 Ophthalmics milestone payments
2.11.4 Ophthalmics royalty rates

Chapter 3 – Leading ophthalmics deals

3.1. Introduction
3.2. Top ophthalmics deals by value

Chapter 4 – Big pharma ophthalmics deals

4.1. Introduction
4.2. How to use big pharma partnering deals
4.3. Big pharma ophthalmics partnering company profiles

Chapter 5 – Big biotech ophthalmics deals

5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech ophthalmics partnering company profiles

Chapter 6 – Ophthalmics partnering contracts directory

6.1. Introduction
6.2. Ophthalmics partnering with contract- by company A-Z
6.3. Ophthalmics partnering with contract- by deal type
6.4. Ophthalmics partnering with contract- by stage of development
6.5. Ophthalmics partnering with contract- by technology type

Chapter 7 – Ophthalmics dealmaking by therapeutic target

7.1. Introduction
7.2. Deals by therapeutic target
Ophthalmics
Age-related macular degeneration
Blindness
Cataracts
Diabetic macular edema
Dry eye
Glaucoma
Ocular hypertension
Retinal detachment
Retinopathy
Uveitis

Appendices

Appendix 1 – Directory of ophthalmics deals by company A-Z: 2010- 2015
Appendix 2 – Directory of ophthalmics deals by deal type: 2010- 2015
Appendix 3 – Directory of ophthalmics deals by stage of development: 2010- 2015
Appendix 4 – Directory of ophthalmics deals by technology type: 2010- 2015
Appendix 5 – Partnering resource center
Online partnering
Partnering events
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form – Upgrades to subscription access products
Order Form – Therapy Reports

List of Table

Figure 1: Ophthalmics partnering since 2010
Figure 2: Big pharma – top 50 – Ophthalmics deals 2010 to 2015
Figure 3: Big pharma ophthalmics deal frequency – 2010 to 2015
Figure 4: Big biotech – top 50 – Ophthalmics deals 2010 to 2015
Figure 5: Big biotech ophthalmics deal frequency – 2010 to 2015
Figure 6: Ophthalmics partnering by deal type since 2010
Figure 7: Most active ophthalmics dealmakers– 2010 to 2015
Figure 8: Ophthalmics partnering by industry sector since 2010
Figure 9: Ophthalmics partnering by stage of development since 2010
Figure 10: Ophthalmics partnering by technology type since 2010
Figure 11: Ophthalmics partnering by specific therapy target since 2010
Figure 12: Ophthalmics deals with a headline value
Figure 13: Ophthalmics deal headline value distribution, US$million – discovery stage
Figure 14: Ophthalmics deal headline value distribution, US$million – preclinical stage
Figure 15: Ophthalmics deal headline value distribution, US$million – phase I stage
Figure 16: Ophthalmics deal headline value distribution, US$million – phase II stage
Figure 17: Ophthalmics deal headline value distribution, US$million – phase III stage
Figure 18: Ophthalmics deal headline value distribution, US$million – regulatory stage
Figure 19: Ophthalmics deal headline value distribution, US$million – marketed stage
Figure 20: Summary median headline value by stage of development, 2010-2015
Figure 21 Ophthalmics deals with upfront payment values
Figure 22: Ophthalmics deal upfront payment distribution, US$million – discovery stage
Figure 23: Ophthalmics deal upfront payment distribution, US$million – preclinical stage
Figure 24: Ophthalmics deal upfront payment distribution, US$million – phase I stage
Figure 25: Ophthalmics deal upfront payment distribution, US$million – phase II stage
Figure 26: Ophthalmics deal upfront payment distribution, US$million – phase III stage
Figure 27: Ophthalmics deal upfront payment distribution, US$million – regulatory stage
Figure 28: Ophthalmics deal upfront payment distribution, US$million – marketed stage
Figure 29: Summary median upfront payments by stage of development, 2010-2015
Figure 30: Ophthalmics deals with milestone payments
Figure 31: Ophthalmics deal milestone distribution, US$million – discovery stage
Figure 32: Ophthalmics deal milestone distribution, US$million – preclinical stage
Figure 33: Ophthalmics deal milestone distribution, US$million – phase I stage
Figure 34: Ophthalmics deal milestone distribution, US$million – phase II stage
Figure 35: Ophthalmics deal milestone distribution, US$million – phase III stage
Figure 36: Ophthalmics deal milestone distribution, US$million – regulatory stage
Figure 37: Ophthalmics deal milestone distribution, US$million – marketed stage
Figure 38: Ophthalmics deals with royalty rates, %
Figure 39: Ophthalmics deal royalty rate distribution, US$million – discovery stage
Figure 40: Ophthalmics deal royalty rate distribution, US$million – preclinical stage
Figure 41: Ophthalmics deal royalty rate distribution, US$million – phase I stage
Figure 42: Ophthalmics deal royalty rate distribution, US$million – phase II stage
Figure 43: Ophthalmics deal royalty rate distribution, US$million – phase III stage
Figure 44: Ophthalmics deal royalty rate distribution, US$million – regulatory stage
Figure 45: Ophthalmics deal royalty rate distribution, US$million – marketed stage
Figure 46: Summary median royalty rate by stage of development, 2010-2015
Figure 47: Top ophthalmics deals by value since 2010
Figure 48: Online partnering resources
Figure 49: Forthcoming partnering events

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *